Tenaya Therapeutics (TNYA) Change in Accured Expenses (2020 - 2026)

Tenaya Therapeutics has reported Change in Accured Expenses for 7 years, with the latest figure at -$2.6 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 38.57% year-over-year to -$2.6 million; the trailing twelve-month figure through Mar 2026 stood at -$202000.0 (up 91.21% YoY), and the FY2025 full-year result was $532000.0, up 111.21% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$2.6 million, down from $1.1 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $2.6 million in Q4 2023, with the low at -$4.4 million in Q1 2024.
• Average Change in Accured Expenses over 5 years is -$14470.6, with a median of $596000.0 recorded in 2024.
• Peak annual rise in Change in Accured Expenses reached 184.99% in 2023, while the deepest fall reached 937.11% in 2023.
• Tracing TNYA's Change in Accured Expenses over 5 years: stood at $2.3 million in 2022, then climbed by 11.28% to $2.6 million in 2023, then sank by 72.3% to $708000.0 in 2024, then jumped by 59.04% to $1.1 million in 2025, then sank by 334.19% to -$2.6 million in 2026.
• The last three Change in Accured Expenses figures came in at -$2.6 million (Q1 2026), $1.1 million (Q4 2025), and $918000.0 (Q3 2025), per Business Quant data.

Peer Comparison